Residual tumor cells remaining in patients after treatment and detected in preclinical models are characterized by significant suppression of MYC [1, 13], and depleting MYC in tumor cells leads to a dormant diapause-like adaptations allowing them to survive under chemotherapy [13]. This evidence concerns the gene MYC and neoplasm.